Stock comparison
Bioventus
LeMaitre Vascular
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BVS
Bioventus
Market cap
$628.7M
Sector
Healthcare
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BVS | LMAT | Winner |
|---|---|---|---|
| Warren Buffett | 36D | 77B | LMAT |
| Benjamin Graham | 52D | 89A | LMAT |
| Philip Fisher | 41D | 81C | LMAT |
| Peter Lynch | 29F | 67B | LMAT |
| Joel Greenblatt | 26F | 56D | LMAT |
| Charlie Munger | 38D | 68D | LMAT |
| Terry Smith | 34F | 69D | LMAT |
Side-by-side metrics
| Metric | BVS | LMAT |
|---|---|---|
| Market cap | $628.7M | $2.23B |
| P/E (TTM) | 25.0x | 37.1x |
| EV/EBIT | 12.0x | 36.6x |
| ROIC (TTM) | 11.77% | 9.43% |
| Gross margin | 67.78% | 72.39% |
| Net margin | 4.94% | 24.35% |
| Revenue CAGR 5y | 7.15% | 12.75% |
| EPS CAGR 5y | - | 19.04% |
| Debt / Equity | 0.1x | 0.5x |
| Dividend yield | 0.0% | 0.84% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BVS leads on
- Debt / Equity0.1xvs 0.5x+79%
- EV/EBIT12.0xvs 36.6x+67%
- P/E (TTM)25.0xvs 37.1x+33%
- ROIC (TTM)11.77%vs 9.43%+20%
LMAT leads on
- Dividend yield0.84%vs 0.0%+100%
- Net margin24.35%vs 4.94%+80%
- Market cap$2.23Bvs $628.7M+72%
- Revenue CAGR 5y12.75%vs 7.15%+44%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.